DeCure for Posterior polymorphous corneal dystrophy 3
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for posterior polymorphous corneal dystrophy 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePosterior polymorphous corneal dystrophy 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for posterior polymorphous corneal dystrophy 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
No drug treatment is mentioned in any of these abstracts. The four reports describe clinical observations and family studies of posterior polymorphous corneal dystrophy. Four young men with both keratoconus and posterior polymorphous corneal dystrophy showed central corneal steepening and irregularity plus large areas of irregular polymorphous opacification at Descemet's membrane. A 58-year-old man with the dystrophy, son of a woman previously reported with Chandler's syndrome, had his cornea and iris examined by light and electron microscopy. In four families, nine persons had typical lesions; two families suggested dominant inheritance, one with less than 100% penetrance, and there were two sporadic cases.
No corneal oedema was present in the family study, and central corneal thickness showed normal values, indicating the corneal endothelium in this dystrophy can maintain normal hydration. A 1992 review notes that basic science research suggests some corneal dystrophies may not be solely corneal abnormalities and that a systemic disorder might help explain high recurrence rates after penetrating keratoplasty. The review discusses recent advances in posterior polymorphous dystrophy and evaluation of posterior corneal anatomy with specular microscopy.
No clinical trial, no drug, no intervention of any kind appears in these abstracts. What is missing is any treatment tested in patients, any animal model work with a drug, any molecular target identified for intervention, and any funding or trial design aimed at altering the course of the disease. Patient stratification by genetic subtype or by presence of concurrent keratoconus has not been attempted in a treatment context.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Optometry and Vision Science · 1989 · 39 citations
Four Cases of Keratoconus and Posterior Polymorphous Corneal Dystrophy
AbstractWe examined four young men with keratoconus and posterior polymorphous corneal dystrophy. All four patients showed central corneal steepening and irregularity, and large areas of irregular polymorphous opacification at the level of Descemet's membrane (in at least one cornea of each patient), which are consistent with posterior polymorphous dystrophy.
AbstractCornea and iris from a 58-year-old man with posterior polymorphous corneal dystrophy were examined by light and electron microscopy. The patient is the son of a woman who was reported previously to have Chandler's syndrome. Clinicopathologic features in the two diseases are discussed in light of controversies surrounding their differential diagnosis.
POSTERIOR POLYMORPHOUS CORNEAL DYSTROPHY OF SCHLICHTING
AbstractPosterior polymorphous corneal dystrophy of Schlichting was studied in 4 families. Nine persons were found with the typical lesions. Two families suggested a dominant mode of inheritance, in one of these with a penetrance less than 100%. There were 2 sporadic cases. No corneal oedema was present, and the central corneal thickness showed normal values, which means that the corneal endothelium in this dystrophy is able to maintain a normal hydrated cornea.
Current Opinion in Ophthalmology · 1992 · 0 citations
Corneal dystrophies
AbstractBasic science research on the corneal dystrophies is uncovering information indicating that these disorders may not all be solely corneal abnormalities. The presence of a systemic disorder may help to explain the high incidence of recurrence of certain corneal dystrophies after penetrating keratoplasty. Recent advances in stromal and crystalline corneal dystrophies and posterior polymorphous dystrophy are discussed, along with evaluation of the posterior corneal anatomy with specular microscopy. Current Opinion in Ophthalmology 1992, 3:438-444
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
